1-2 of 2
Donna Hogge, MD PhD FRCPC
Close
Sort by
Journal Articles

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Bruno C. Medeiros, MD, Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Laura F Newell, MD, Tara L. Lin, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, Donna Hogge, MD PhD FRCPC, Scott R. Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Daniel H. Ryan, MD, Antje Hoering, PhD, Michael T. Chiarella, Arthur C. Louie, MD, Geoffrey L. Uy, MD
Journal: Blood
Blood (2016) 128 (22): 902.
https://doi.org/10.1182/blood.V128.22.902.902
Published: 2016
Journal Articles

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

Jeffrey E. Lancet, MD, Antje Hoering, PhD, Geoffrey L. Uy, MD, Jorge E. Cortes, MD, Laura F Newell, MD, Tara L. Lin, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, Donna Hogge, MD PhD FRCPC, Scott R. Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Daniel H. Ryan, MD, Michael T. Chiarella, Arthur C. Louie, MD, Bruno C. Medeiros, MD
Journal: Blood
Blood (2016) 128 (22): 906.
https://doi.org/10.1182/blood.V128.22.906.906
Published: 2016